Fate Therapeutics Inc (FATE)

[jondoeuk]

ASH abstracts

3297 Knock-in of the BCL2 G101V Mutation in Human iPSC-Derived NK Cells Generates Venetoclax Resistance and Improves Activity Against Venetoclax Resistant AML https://ash.confex.com/ash/2022/webprogram/Paper160203.html

666 A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy https://ash.confex.com/ash/2022/webprogram/Paper163871.html

3289 Targeted Genomic Insertion of Cars in iPSC-Derived Macrophages Leads to Improved Expression and Anti-Tumor Activity https://ash.confex.com/ash/2022/webprogram/Paper159752.html

1983 Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors https://ash.confex.com/ash/2022/webprogram/Paper163884.html